person · Reporting owner
BIENAIME JEAN JACQUES
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | April 14, 2026 | September 28, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 24, 2018 | September 24, 2018 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Director | June 10, 2026 | June 12, 2026 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date April 14, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14 | Direct | 9,160 |
Reported balance
After 2026-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.
F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.
IMMUNIC, INC.
Report date September 24, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,500 |
Reported balance
After 2018-09-24 transaction · row 1
1 source rowRow 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,424 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Immunome Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09 | Direct | 9,897 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Keros Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,592 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOMARIN PHARMACEUTICAL INC
Report date May 20, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 473,792 |
Reported balance
After 2024-05-20 transaction · row 1
1 source rowRow 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Jean-Jacques Bienaime Family Trust | 247,333 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 247,333 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 1 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 100 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 2 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 100 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2024 Filed May 13, 2024 19:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 20,000 | $81.62 | $1,632,400.00 |
DisclosureSEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,994 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| May 09, 2024 Filed May 13, 2024 19:57 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 20,000 | $63.10 | $1,262,000.00 |
DisclosureSEC source: 0001048477-24-000079 · wk-form4_1715630235.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 20,000 | $91.26 | $1,825,200.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,994 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| April 12, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 20,000 | $63.10 | $1,262,000.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 20,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 20,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 20,000 | $90.99 | $1,819,800.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 474,994 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 20:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 20,000 | $63.10 | $1,262,000.00 |
DisclosureSEC source: 0001048477-24-000063 · wk-form4_1713212473.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 494,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 85,209 | $83.87 | $7,146,478.83 |
DisclosureSEC source: 0001048477-24-000038 · wk-form4_1710895245.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,994 Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $86.71 | $86,713.00 |
DisclosureSEC source: 0001048477-24-000032 · wk-form4_1709850926.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 560,203 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:35 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $85.51 | $85,510.00 |
DisclosureSEC source: 0001048477-24-000032 · wk-form4_1709850926.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 561,203 Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $90.35 | $90,350.00 |
DisclosureSEC source: 0001048477-24-000018 · wk-form4_1709244306.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,203 Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 24,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000018 · wk-form4_1709244306.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,203 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 35,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000018 · wk-form4_1709244306.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 538,277 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 22:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 82,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000018 · wk-form4_1709244306.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,302 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2021 through 2023 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2024, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · derivative · entry 10 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 15,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $88.28 | $1,324,200.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,602 F3 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| February 09, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $63.10 | $946,500.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 15,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $89.77 | $1,346,550.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,602 F3 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $63.10 | $946,500.00 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| January 18, 2024 Filed Feb 12, 2024 22:20 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 40 | $92.60 | $3,703.90 |
DisclosureSEC source: 0001048477-24-000010 · wk-form4_1707776385.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 419,602 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F2 · price: The price in column 4 is the weighted average price. The purchase price actually paid ranged from $92.595 to $92.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · derivative · entry 10 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $96.38 | $963,800.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,162 F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $63.10 | $631,000.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $98.19 | $981,900.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,162 F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $63.10 | $631,000.00 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| January 08, 2024 Filed Jan 11, 2024 19:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 50 | $99.05 | $4,952.59 |
DisclosureSEC source: 0001048477-24-000002 · wk-form4_1705002030.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,162 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-23-000064 · wk-form4_1703283254.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,000 Underlying: Common Stock · 10,000 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $93.99 | $939,900.00 |
DisclosureSEC source: 0001048477-23-000064 · wk-form4_1703283254.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,112 F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| December 21, 2023 Filed Dec 22, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $63.10 | $631,000.00 |
DisclosureSEC source: 0001048477-23-000064 · wk-form4_1703283254.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. Read SEC document |
| December 01, 2023 Filed Dec 13, 2023 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-23-000057 · wk-form4_1702428903.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,112 F2 · price: Restricted stock units granted on December 1, 2023. Price not applicable. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 21:25 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 40,696 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001209191-23-054838 · doc4.xml · derivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,696 Underlying: Common Stock · 40,696 shares Expires 2033-11-06 F1 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on November 7, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date. Read SEC document |
| October 04, 2023 Filed Dec 13, 2023 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | OtherCommon Stock | 10 | $85.57 | $855.66 |
DisclosureSEC source: 0001048477-23-000057 · wk-form4_1702428903.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,742 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 10 shares, with the reporting person's sale of shares at a price of $99.56 on April 10, 2023. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
| August 08, 2023 Filed Aug 9, 2023 23:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,000 | $88.29 | $529,740.00 |
DisclosureSEC source: 0001048477-23-000031 · wk-form4_1691622294.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,732 Read SEC document |
| August 07, 2023 Filed Aug 9, 2023 23:05 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 4,000 | $88.10 | $352,400.00 |
DisclosureSEC source: 0001048477-23-000031 · wk-form4_1691622294.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 428,732 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,294 | $0.00 Strike: $61.44 | $0.00 |
DisclosureSEC source: 0001209191-23-037794 · doc4.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 2,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037794 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,493 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 7,370 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,370 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 39,130 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,130 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 33,644 | $93.93 | $3,160,180.92 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,732 Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 6,337 | $93.93 | $595,234.41 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,376 Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,370 | $67.81 | $499,759.70 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2023 Filed May 16, 2023 21:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 39,130 | $67.81 | $2,653,405.30 |
DisclosureSEC source: 0001209191-23-029870 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-029509 · doc4.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,130 Underlying: Common Stock · 30,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,561 | $95.22 | $529,518.42 |
DisclosureSEC source: 0001209191-23-029509 · doc4.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,213 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $94.94 to $95.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 24,439 | $94.55 | $2,310,707.45 |
DisclosureSEC source: 0001209191-23-029509 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 431,774 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $93.935 to $94.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:58 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 30,000 | $67.81 | $2,034,300.00 |
DisclosureSEC source: 0001209191-23-029509 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| May 10, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 8,547 | $95.34 | $814,870.98 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,213 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F7 · price: The price in column 4 is the weighted average price. The price actually received ranged from $95.115 to $95.81. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.